All News

DNA,genotyping,gene,sequencing

Molecular profiling of RA synovium predicts biologic responses

d Jack Cush, MD

Machine learning analysis of pre-treatment synovial tissue biopsy from rheumatoid arthritis (RA) patients starting either etanercept (ETN), tocilizumab (TCZ) and rituximab (RTX) revealed

Read Article
human figures on blue circle

1 in 5 Patients are Unaware of their Arthritis Diagnosis

d Jack Cush, MD

Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA.  Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).

Read Article
397_relapsing_polychondritis_slide_4_springer_high.jpg

Manifestations and Treatment in Relapsing Polychondritis

d Jack Cush, MD

A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.

Read Article
hospital,surgery

Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients

d Jack Cush, MD

More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the perioperative management of DMARDs and found inconsistencies and low quality evidence, with great reliance on conditional (expert opinion) recommendations.

Read Article
hip-fracture.jpg

Osteoporosis treatment benefits people older than 80

d EurekAlert!

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Read Article
Lung,cancer,nci

Interstitial Lung Disease and Lung Cancer Risk

d Jack Cush, MD

A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer.

Read Article
Sulfasalazine as a preventative against Pneumocystis (PJP). 594 RA pts & 848 Rx episodes - 181 on SSZ, 667 controls. W/ 850 Pt-Yrs F/U, 21developed PCP, 3 died of PCP. SSZ significantly lowered PJP risk (p = 0.003, rate ratio = 0.05; 95% CI 0.00–0.34). https://t.co/PAgBaJGldR https://t.co/VV3MvVEGal

Links:

Dr. John Cush RheumNow ( View Tweet)
Osteoporosis treatment benefits people older than 80 People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San https://t.co/ry3V4Nmq7E
Dr. John Cush RheumNow ( View Tweet)
New download available on biomarkers https://t.co/rFeApBnHav https://t.co/vwjog6ILJU

Links:

Dr. John Cush RheumNow ( View Tweet)
Interstitial Lung Disease and Lung Cancer Risk A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer. https://t.co/SdOT28qVfr https://t.co/6KhAijhfHw

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/IDeEvitIrB
Dr. John Cush RheumNow ( View Tweet)
Biologic survival study of British Assoc. of Dermatologists Biologics Register (11/07-6/23) looked at 19,034 Rx courses (median F/U 2.3 yrs), of TNFi, IL-12/23i, IL-17i, & IL-23i. IL-23i (GUS & RIS) had best survival (~1.93yrs) for efficacy & safety (broadalumab the least) https://t.co/aAULb0e3o9
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis have more adverse pregnancy outcomes. Swedish Medical Birth Register study pre- & post SSc Dx (94 vs 978) finds incr risk post SSc for preeclampsia (RR 3.8), preterm birth (3.3), & caesarean (2.5). No incr of maternal or neonatal death, nor stillbirth https://t.co/9PWREN62r0
Dr. John Cush RheumNow ( View Tweet)
Martinque, Afro-Caribbean population (n 354 800) study(2004-2022) of 33 AOSD pts (71%F; 79% systemic; 21% chr articular); 91% met Yamaguchi criteria; features as expected but more Pulmonary Dz(51%; 94% w/ a systemic pattern). Half Dx < age 35 yrs. Prevalence 7.6 /100 000 mean https://t.co/QWyfNuvhkl
Dr. John Cush RheumNow ( View Tweet)
NHANES study (1999–2018) of 38,272 participants looked at the neutrophil-to-albumin ratio (NPAR), & elevated NPAR significantly assoc w/ an increased risk of RA (ORtertile3vs1 = 1.27), esp if NPAR > 13.6. NPAR superior to SI), SIRI, PLR, MLR, & NLR. https://t.co/asLc6ghz7w https://t.co/2dAhIvekGA

Links:

Dr. John Cush RheumNow ( View Tweet)
NHANES study (2007 to 2020) of 19,904 participants (≥ 20 years), including 1,477 RA pts. Prevalence of kidney stones was higher in RA (17% vs. 8%, p < 0.001) (OR = 1.77) https://t.co/0NZKQdQWR8 https://t.co/BRZ1RTNh5W

Links:

Dr. John Cush RheumNow ( View Tweet)
RA study shows rapid remission (DAS28-CRP < 2.6 <12 wks) occurred in 28% of 865 pts & assoc. w/ better respsonses at week 26. Also rapid remission had signif. 5 yr benefits (SJC, TJC, Fatigue, HAQ, pain, & most PRO outcomes. https://t.co/2tvxS8oXP2 https://t.co/YAFGAri3Uj

Links:

Dr. John Cush RheumNow ( View Tweet)
10-20% of IBD pts have IBD-assoc. spondyloarthritis, as either peripheral arthritis or axial Dz, subclinical gut inflammation w/ IL-23–IL-17–TNFα playing central roles. TNFi & JAKi Rx is effective, but IL-17i may exacerbate IBD (vedolizumab??) Review here>> https://t.co/kNIAi55Y7z
Dr. John Cush RheumNow ( View Tweet)
HHS secretary Abruptly Cancels USPSTF Meeting on July 10 - to discuss diet, physical activity, and weight loss to prevent cardiovascular disease in adults. An HHS spokesperson did not give a reason. https://t.co/IqNOUWeVA4 https://t.co/0AmxQ1ZAcQ

Links:

Dr. John Cush RheumNow ( View Tweet)
CMS to Test Prior Authorization Model in Traditional Medicare The Centers for Medicare & Medicaid Services (CMS) announced a new experimental model late last week to streamline some prior authorizations under the traditional Medicare program, but some politicians and experts https://t.co/o8iV9Bb6Ir
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×